The life sciences encompass research fields that have a direct impact on our quality of our health, food and environment including pharmaceuticals, genetics, systems biology and biotechnology. Now, in the post-genomic era, the domain has undergone a revolution in terms of research approaches, new infrastructure needs and technology developments and, now more than ever, we are witnessing new developments which directly impact on our lives.
These developments are taking place throughout the world and, in order for Europe to remain competitive with the US and Asia, the necessary critical mass of expertise and resources must be made available in a coordinated manner. Currently, R & D investment is fragmented among numerous funding bodies across Europe. Now, with support from the European Commission, the ESF will launch this unique initiative to bring together these funding bodies and life sciences researchers to develop a more coordinated strategy for planning and investing in life sciences research. The establishment of EuroBioFund is well timed given that the EU’s New Seventh Framework Programme (FP7), will be launched officially as of January 1 2007, with a budget of €50 billion to invest in scientific research and innovation.
The three key objectives of the EuroBioFund are:
1. Provide a platform for funding organisations and life science researchers to foster joint research initiatives through networking and brokerage: EuroBioForum
2. Help organise research communities and facilitate bottom-up generation of research programmes of European scale and scope: EuroBioGenerator
3. Shape a new funding way in Europe by helping to develop joint investments and funding of life sciences research: EuroBioAccess
EuroBioFund’s new approach will centre on an annual conference, EuroBioForum, and the first will be held in Helsinki 14-15 December 2006. For funders this is a unique opportunity to engage with key life science research groups presenting proposals for cutting-edge pan-European research programmes. From the researcher’s side, EuroBioForum provides a forum to promote important research topics to those funding and investing in life sciences R & D.
‘Moving toward a more coordinated approach to R & D investment in the life sciences is a challenging but necessary step if Europe is to remain an important global player in life sciences and biotechnology research,’ says Wouter Spek, Director of EuroBioFund.
Wouter Spek | alfa
Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel
The Nagoya Protocol Creates Disadvantages for Many Countries when Applied to Microorganisms
05.12.2016 | Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
05.12.2016 | Power and Electrical Engineering
05.12.2016 | Materials Sciences
05.12.2016 | Power and Electrical Engineering